These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16103498)

  • 21. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
    Blank PR; Schwenkglenks M; Moch H; Szucs TD
    Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutrophil elastase predicts trastuzumab responsiveness in metastatic breast cancer.
    Yamashita J; Akizuki M; Jotsuka T; Harao M; Nakano S
    Breast J; 2006; 12(3):288. PubMed ID: 16684339
    [No Abstract]   [Full Text] [Related]  

  • 24. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
    Bult P; Tjan-Heijnen VC; van Krieken H
    Ned Tijdschr Geneeskd; 2006 Jul; 150(26):1481; author reply 1481-3. PubMed ID: 16875274
    [No Abstract]   [Full Text] [Related]  

  • 26. Inconsistency of HER2 test raises questions.
    Tuma RS
    J Natl Cancer Inst; 2007 Jul; 99(14):1064-5. PubMed ID: 17623788
    [No Abstract]   [Full Text] [Related]  

  • 27. Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer.
    Simoens S
    Pharmacoeconomics; 2007; 25(3):181-5. PubMed ID: 17335304
    [No Abstract]   [Full Text] [Related]  

  • 28. [Assessment of HER2 status in breast cancer].
    Penault-Llorca F; Cayre A
    Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More than one way to look for HER2.
    Check W
    CAP Today; 1999 Mar; 13(3):1, 40-2, 46, passim. PubMed ID: 10350906
    [No Abstract]   [Full Text] [Related]  

  • 30. Herceptin (R): monoclonal antibody therapy for metastatic breast cancer.
    McGahan L
    Issues Emerg Health Technol; 1998; (4):1-4. PubMed ID: 11811211
    [No Abstract]   [Full Text] [Related]  

  • 31. Roche responds to the 'Herceptin or deception' article.
    Petersen S
    N Z Med J; 2006 Jul; 119(1237):U2069; author reply U2069. PubMed ID: 16862210
    [No Abstract]   [Full Text] [Related]  

  • 32. Skipping for herceptin funds.
    Harrison J
    Nurs N Z; 2007 Nov; 13(10):4. PubMed ID: 18084962
    [No Abstract]   [Full Text] [Related]  

  • 33. Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?
    Coulson SG; Kumar VS; Manifold IM; Hatton MQ; Ramakrishnan S; Dunn KS; Purohit OP; Bridgewater C; Coleman RE
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):289-93. PubMed ID: 20347281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy.
    Bellati F; Napoletano C; Ruscito I; Liberati M; Panici PB; Nuti M
    J Clin Oncol; 2010 Jul; 28(21):e369-70; author reply e371. PubMed ID: 20479394
    [No Abstract]   [Full Text] [Related]  

  • 35. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
    Dent R; Clemons M
    Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
    [No Abstract]   [Full Text] [Related]  

  • 36. HER2-positive advanced breast cancer.
    Robert NJ; Favret AM
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):293-302. PubMed ID: 17512450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dramatic benefit seen in new cancer treatment. Herceptin plus chemo shows greatest gains compared to any other regimens; may eliminate need for mastectomy.
    Health News; 2005 Nov; 11(11):8-9. PubMed ID: 16294429
    [No Abstract]   [Full Text] [Related]  

  • 38. Herceptin (trastuzamab) in advanced breast cancer.
    Stebbing J; Copson E; O'Reilly S
    Cancer Treat Rev; 2000 Aug; 26(4):287-90. PubMed ID: 10913383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working?
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):48a-48b. PubMed ID: 19856610
    [No Abstract]   [Full Text] [Related]  

  • 40. [Her2/neu receptor: one of the basic factors rendering tailored therapy feasible in breast cancer patients].
    Kulka J
    Orv Hetil; 2005 Apr; 146(17):785-90. PubMed ID: 17918634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.